Acurx Pharmaceuticals, Inc.
ACXP
Rank in Stocks
#30138
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical... Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
Share Price
$1.06
Last synced: 2026-11-09
Market Cap
$5.89M
Change (1 day)
0.00%
Change (1 year)
-81.00%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Acurx Pharmaceuticals, Inc. (ACXP)
Category
Healthcare
EPS for Acurx Pharmaceuticals, Inc. (ACXP)
EPS as of June 2026 TTM: $-3.55
According to Acurx Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-3.55. At the end of 2025 the company had an EPS of $-5.32, an increase over its 2024 EPS of $-17.59.
EPS history for Acurx Pharmaceuticals, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.55 | -33.27% |
| 2025 | $-5.32 | -69.76% |
| 2024 | $-17.59 | -23.55% |
| 2023 | $-23.01 | 2.91% |
| 2022 | $-22.36 | -10.42% |
| 2021 | $-24.96 | 168.97% |
| 2020 | $-9.28 | -22.67% |
| 2019 | $-12.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -541.13% |
US
|
|
| $-7.07 | 99.15% |
US
|
|
| $-5.29 | 49.01% |
AU
|
|
| $12.88 | -462.82% |
BE
|
|
| $21.56 | -707.32% |
NL
|
Questions about Acurx Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Acurx Pharmaceuticals, Inc.'s earnings per share (EPS)?
Acurx Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-3.55, as of Jun 2026.
What was Acurx Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Acurx Pharmaceuticals, Inc.'s earnings per share (EPS) was $-5.32, compared with $-17.59 in 2024.
How has Acurx Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Acurx Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2025 ($-5.32) and lowest in 2021 ($-24.96).
How does Acurx Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Acurx Pharmaceuticals, Inc.'s earnings per share (EPS) ($-3.55) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.